What’s Next for Respiratory Virus Vaccines?

Respiratory syncytial virus preventives for children in Australia: current landscape and future directions

A review of advancements in respiratory syncytial virus (RSV) prevention within Australia, focusing on the recent introduction of nirsevimab, a long-acting monoclonal antibody, and Abrysvo, a maternal RSV vaccine.

What’s Next for Respiratory Virus Vaccines?

This infographic breaks down the current vaccine modalities and explores the critical role mucosal immunity may play in future vaccine strategies...

RSV immunisation has already saved Australia millions in hospital cost

A statewide immunisation program for infants against respiratory syncytial virus (RSV), which began in 2024, has already resulted in 57% lower than expected hospitalisations in WA, saving the health system $6.2–6.9 million, according to Australian experts. The experts say the availability of vaccines is “an era defining advancement in RSV prevention.”

Nirsevimab Cuts RSV Hospitalizations in Spanish Study

TOPLINE: The introduction of universal passive immunisation with nirsevimab, a long-acting monoclonal antibody, led to significant reductions in hospitalizations and paediatric intensive care admissions for respiratory syncytial virus–associated lower respiratory tract infections (RSV-LRTIs), particularly benefiting infants younger than 6 months. METHODOLOGY: Researchers carried out a prospective observational study at a tertiary hospital in Spa…